Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
DL03
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
- NCT04686305 ↗
- Recruiting
- AstraZeneca
- Deep
We haven't built an HCP commentary report on DL03 (T-DXd, durvalumab and 5 more in Locally Advanced or Metastatic Non-Small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on DL03 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| Podcasts | 15 | |
| YouTube | 10 | |
| X threads | 7 |
The trial
ClinicalTrials.gov- Official title
- A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Interventions
- T-DXd; Durvalumab; Cisplatin; Carboplatin; Pemetrexed; Volrustomig; Rilvegostomig
- Arms
- Arm 1A: T-DXd, Durvalumab and Cisplatin · Experimental
- Arm 1B: T-DXd, Durvalumab and Carboplatin · Experimental
- Arm 1C: T-DXd, Durvalumab and Pemetrexed · Experimental
- Arm 1D: T-DXd · Experimental
- Arm 3A: T-DXd and Volrustomig · Experimental
- Arm 3B: T-DXd, Volrustomig and Carboplatin · Experimental
- Arm 4A: T-DXd and Rilvegostomig · Experimental
- Arm 4B T-DXd and Rilvegostomig with Carboplatin · Experimental
- Arm 5A: T-DXd and Volrustomig · Experimental
- Arm 5B: T-DXd and Volrustomig · Experimental
- Enrollment
- 304 (estimated)
- Primary outcomes
- Frequency of AEs and SAEs
- Sponsor
- AstraZeneca with Daiichi Sankyo
- Start
- Mar 9, 2021
- Primary completion
- Jun 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04686305 · updated Apr 13, 2026
Publications
linked from the registry- Planchard D, Kim HR, Suksombooncharoen T, Li R, Cortinovis D, Han JY, Samol J, Runglodvatana Y, Lee KY, Chang GC, Lee CH, Kowalski D, Saw SPL, Huang Y, Ruiter G, Ahn MJ, Yang TY, Yang CT, Sookprasert A, Nakajima EC, Alfon J, McEwen R, Chang YT, Yang JC. Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial. J Thorac Oncol. 2026 May;21(5):103541. doi: 10.1016/j.jtho.2025.12.080. Epub 2025 Dec 23. PubMed 41448488